Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (MeRes-1Extend)

MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions

MeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe, Brazil and South Africa. Primary outcome of study will be Proportion of population reporting Major Adverse Cardiac Events at 6 months from the day of index Procedure.

Study Overview

• Status: Unknown
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Device: MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Brazil
  • SP
    • Sao Paulo, SP, Brazil, 04012-909
      • Instituto Dante Pazzanese de Cardiologia
• Indonesia
  • Jakarta, Indonesia, 12950
    • Medistra Hospital
• Macedonia, The Former Yugoslav Republic of
  • Skopje, Macedonia, The Former Yugoslav Republic of, 1000
    • University Clinic of Cardiology
• Malaysia
  • Kuala Lumpur, Malaysia, 50400
    • Institut Jantung Negara

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

General Inclusion Criteria:

1. Male or female subjects ≥ 18 years of age
2. Subject is able to sign written Informed Consent Form (ICF)
3. Subjects with symptomatic myocardial ischemia, chronic stable angina
4. The patient has planned intervention of a single de novo lesion in native epicardial vessel
5. Subject who is an acceptable candidate for Coronary Artery Bypass Grafting (CABG)
6. Subject is not participating in any other clinical investigation/study and agrees not to participate in any other clinical investigation/study for a period of 3 years following the index procedure.
7. Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms and OCT as per protocol.

Angiographic Inclusion Criteria:

1. Subject with maximum two treatable de novo lesions located maximum one per native epicardial vessel located in major artery or branch, with reference vessel diameter between 2.75, 3.00 and 3.5 mm by on line QCA.
2. Target lesion length ≤ 20 mm.
3. Subjects with Lesion(s), with a visually estimated stenosis of ≥ 50% and < 100% with a TIMI flow of ≥ 1.

Exclusion Criteria:

General Exclusion Criteria:

1. Subjects unable to provide written informed consent.
2. Pregnant or nursing mother and those who plan pregnancy during the clinical investigation (female patients must have a negative pregnancy test done within 7 days prior to the index procedure and effective contraceptive must be used during participation in this clinical investigation).
3. Subjects with known allergy to Poly-L-Lactide (PLLA), Poly-D,L-Lactide (PDLLA), Sirolimus (Rapamycin) or its any analog or derivative, clopidogrel, ticlopidine, prasugrel, contrast media, platinum, ticagrelor and any drug in dual antiplatelet therapy including aspirin, both heparin and bivalirudin.
4. Subject diagnosed with Acute Myocardial Infarction (AMI) within 7 days preceding the index procedure, as indicated by elevated levels of cardiac enzymes and/or ST segment changes in Electro Cardio Gram (ECG).
5. Subject with history of previous revascularization procedures including CABG and Percutaneous Coronary Intervention (PCI).
6. Subject with vascular aneurysms, cardiac arrhythmias, congestive cardiac failure having LVEF < 30%, cardiac tamponade.
7. Recipient of an organ in an organ transplant procedure or is on a waiting list for any organ transplant.
8. Subjects receiving immunosuppression therapy or having known immunosuppressive or autoimmune disease.
9. Subjects with history of stroke, Cerebro Vascular Accident (CVA) or Transient Ischemic neurological Attack (TIA). Patients with renal insufficiency where creatinine levels are more than 1.3 mg/dl, known aplastic anaemia, chronic liver disease, platelet count <100,000 cells/mm3, a WBC of < 3,000 cells/mm3.
10. Subjects planned for elective surgery within the first 12 months after the procedure that will require discontinuing dual antiplatelet therapy
11. Subject has a history of bleeding diathesis or coagulatory disease, refuses blood transfusion, significant gastrointestinal or urinary bleed within the past 12 months.
12. Subject having extensive peripheral vascular disease that precludes safe 6F sheath insertion.
13. Subject having a history of paradoxical exercise induced vasoconstriction that is consistent with myocardial bridging in the coronary anatomy.
14. Subjects participating in another clinical investigation.
15. Subjects with short life expectancy such as cancer, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or other co-morbid conditions that would limit compliance with the follow-up schedule of the study.

Angiographic Exclusion Criteria:

1. Subjects who are non-candidates for PCI.

2. Any of the target lesions meets any of the following criteria:

   1. Aorto-ostial location (within 3 mm)
   2. Lesion located in left main coronary artery
   3. Lesion located within 2 mm of origin of the LAD or LCx
   4. Lesion that involves a bifurcation with a side branch ≥ 2mm in diameter and ostial lesion > 40% stenosed by visual estimation or side branch requiring intervention
   5. Total occlusion (TIMI Flow 0), prior to wire crossing
   6. Extreme tortuosity proximal to or within the lesion
   7. Lesions having heavy calcification
   8. Extreme angulation (≥ 90 %) proximal to or within the lesion

3. Evidence of previous revascularization:

   1. Previous PCI with or without restenosis from previous intervention
   2. Arterial or venous graft with or without lesion located within the graft or distal to a diseased arterial or saphenous vein graft
4. The target vessel contains visible thrombus.
5. Another (clinically significant or potentially significant) lesion left untreated within target vessels (including side branch) or another significant vessel.
6. Subject requiring or potentially requiring interventional procedures other than pre-dilatation and study device implantation and post dilatation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: MeRes100 - BRS; MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System	Device: MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System; MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure.	6 Month
Primary Safety Endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE) reporting at 6 months (180 days) from the day of index procedure	6 Month

Collaborators and Investigators

• Sponsor: Meril Life Sciences Pvt. Ltd.
• Investigators: Principal Investigator: Dr. Alexandre Abizaid, Dante Pazzanese Hospital, Sao Paulo, Brazil

Publications and helpful links

General Publications

• Abizaid A, Kedev S, Ali RBM, Santoso T, Cequier A, van Geuns RVG, Chevalier B, Hellig F, Costa R, Onuma Y, Costa JR Jr, Serruys P, Bangalore S. Imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: The MeRes-1 extend trial. Catheter Cardiovasc Interv. 2021 Nov 15;98(6):1102-1110. doi: 10.1002/ccd.29396. Epub 2020 Dec 2.

Study record dates

Study Major Dates

• Study Start (Actual): February 2, 2016
• Primary Completion (Actual): October 5, 2017
• Study Completion (Anticipated): July 5, 2020

Study Registration Dates

• First Submitted: December 7, 2015
• First Submitted That Met QC Criteria: January 21, 2016
• First Posted (Estimate): January 26, 2016

Study Record Updates

• Last Update Posted (Actual): August 17, 2018
• Last Update Submitted That Met QC Criteria: August 16, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Keywords: Coronary Artery Disease; MeRes-1 Extend; MeRes100; Sirolimus Eluting Bioresorbable Vascular Scaffold System
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Sirolimus
• Other Study ID Numbers: MER/EX

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No